Explanation of Conflict of Interest Disclosure Parts:
Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2008-Present)
Part Two: Income Sources & Equity of $10,000 or greater
Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2008-Present):
Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2008-Present)
Part Five: My primary employer is a pharmaceutical**/**biotech/medical device company.

ACNP 2012 Council Disclosures

John Csernansky: Eli Lilly & Company, *Part 1*

Ronald Duman: Eli Lilly & Company, Lundbeck, Johnson & Johnson, Taisho, Bristol Myers Squibb, Forest, Repligen *Part 1*; Eli Lilly & Company, Lundbeck, Johnson & Johnson, Repligen, Forest, *Part 4*

Alan Frazer: Lundbeck, Takeda, Dey Pharmaceuticals, Eli Lilly & Company, *Part 1*; Editor-in-Chief of Intl J. Neuropsychopharmacology (stipend from Cambridge University Press) *Part 2*; Lundbeck, *Part 4*

Mark Geyer: ACNP (Neuropsychopharmacology), Abbott, Addex, Cerca Insights, Merck, Omeros, San Diego Instruments, Sepracor, Takeda, Teva, Pfizer (spouse), Astra-Zeneca (spouse), *Part 1*; Omeros, San Diego Instruments, *Part 2*; Intracellular Therapies, Johnson & Johnson, Pfizer (spouse), Astra-Zeneca (spouse), Bristol-Myers (spouse) *Part 4*

John Krystal: Aisling Capital, LLC, Astra Zeneca, Biocortech, Brintall & Nicolini, Inc, Easton Associates, Inc., Gilead Sciences, Inc., GSK, Janssen, Lundbeck, Medivation, Merz, MK Medical Communications, , F. Hoffman-LaRoche, Ltd., SK Holdings Co., Sunovion, Takeda Industries, Teragenex, Teva, *Part 1*; Biological Psychiatry Editor, *Part 2*; Janssen Research Foundation, *Part 4*
<u>Patents and Inventions</u>
1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. Patent #:5,447,948.September 5, 1995
2) Co-inventor with Dr. Gerard Sanacora on a filed patent application by Yale University related to targeting the glutamatergic system for the treatment of neuropsychiatric disorders (PCTWO06108055A1).
3) Intranasal Administration of Ketamine to Treat Depression (pending)

David Kupfer: Sevier (spouse), Guilford Press (spouse), *Part 1*; American Psychiatric Association, Sevier (spouse), *Part 2*

David Lewis: BMS, Bioline RX, Merck, SK Life Science, *Part 1*; BMS Foundation, BMS, Curridium LTD, Pfizer, *Part 4*

Eric Nestler: PsychoGenics, Merck, Neurologix, *Part 1*; PsychoGenics, Merck, Neurologix, *Part 2*; Merck, PsychoGenics, *Part 4*

David Rubinow: Dialogues of Clinical Neuroscience, CME Outfitters (Chair's Summit), *Part 1*; Servier/Dialogues of Clinical Neuroscience, *Part 2*; Foundation of Hope, *Part 4*

Council Members with No Disclosures
Karen Berman
Linda Brady
Cindy Ehlers
Ronnie Wilkins, Executive Director